{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T20:53:51Z","timestamp":1785444831703,"version":"3.56.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T00:00:00Z","timestamp":1723507200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T00:00:00Z","timestamp":1723507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["5R01CA246209"],"award-info":[{"award-number":["5R01CA246209"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Institute of Health","award":["1R41CA261292-01"],"award-info":[{"award-number":["1R41CA261292-01"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s11095-024-03755-6","type":"journal-article","created":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T19:02:21Z","timestamp":1723575741000},"page":"1855-1867","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Fecal SN-38 Content as a Surrogate Predictor of Intestinal SN-38 Exposure and Associated Irinotecan-induced Severe Delayed-Onset Diarrhea by a Novel Use of the Spectrofluorimetric Method"],"prefix":"10.1007","volume":"41","author":[{"given":"Zicong","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vesna Tumbas","family":"\u0160aponjac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashim","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songpol","family":"Srinual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taijun","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongjin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2744-6294","authenticated-orcid":false,"given":"Ming","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,13]]},"reference":[{"issue":"7","key":"3755_CR1","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.ctrv.2006.07.001","volume":"32","author":"C Fuchs","year":"2006","unstructured":"Fuchs C, Mitchell EP, Hoff PM. Irinotecan in the treatment of colorectal cancer. Cancer Treat Rev. 2006;32(7):491\u2013503.","journal-title":"Cancer Treat Rev"},{"issue":"4","key":"3755_CR2","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1634\/theoncologist.10-4-250","volume":"10","author":"A Venook","year":"2005","unstructured":"Venook A. Critical evaluation of current treatments in metastatic colorectal cancer. Oncologist. 2005;10(4):250\u201361.","journal-title":"Oncologist"},{"issue":"8 Suppl 6","key":"3755_CR3","first-page":"72","volume":"12","author":"JR Hecht","year":"1998","unstructured":"Hecht JR. Gastrointestinal toxicity or irinotecan. Oncology (Williston Park). 1998;12(8 Suppl 6):72\u20138.","journal-title":"Oncology (Williston Park)"},{"issue":"13","key":"3755_CR4","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1056\/NEJM200009283431302","volume":"343","author":"LB Saltz","year":"2000","unstructured":"Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med. 2000;343(13):905\u201314.","journal-title":"N Engl J Med."},{"issue":"7","key":"3755_CR5","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/0006-2952(96)00457-1","volume":"52","author":"LP Rivory","year":"1996","unstructured":"Rivory LP, Bowles MR, Robert J, Pond SM. Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by Human Liver Carboxylesterase. Biochem Pharmacol. 1996;52(7):1103\u201311.","journal-title":"Biochem Pharmacol"},{"issue":"4","key":"3755_CR6","doi-asserted-by":"publisher","first-page":"245","DOI":"10.2165\/00003088-199733040-00001","volume":"33","author":"GG Chabot","year":"1997","unstructured":"Chabot GG. Clinical pharmacokinetics of irinotecan. Clin Pharmacokinet. 1997;33(4):245\u201359.","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"3755_CR7","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s00280-008-0769-8","volume":"63","author":"IR Younis","year":"2009","unstructured":"Younis IR, Malone S, Friedman HS, Schaaf LJ, Petros WP. Enterohepatic recirculation model of irinotecan (CPT-11) and metabolite pharmacokinetics in patients with glioma. Cancer Chemother Pharmacol. 2009;63(3):517\u201324.","journal-title":"Cancer Chemother Pharmacol"},{"key":"3755_CR8","doi-asserted-by":"publisher","first-page":"115032","DOI":"10.1016\/j.taap.2020.115032","volume":"398","author":"R Sun","year":"2020","unstructured":"Sun R, Zhu L, Li L, Song W, Gong X, Qi X, et al. Irinotecan-mediated diarrhea is mainly correlated with intestinal exposure to SN-38: Critical role of gut Ugt. Toxicol Appl Pharmacol. 2020;398:115032.","journal-title":"Toxicol Appl Pharmacol"},{"issue":"47","key":"3755_CR9","doi-asserted-by":"publisher","first-page":"19143","DOI":"10.1073\/pnas.1319123110","volume":"110","author":"S Chen","year":"2013","unstructured":"Chen S, Yueh MF, Bigo C, Barbier O, Wang K, Karin M, et al. Intestinal glucuronidation protects against chemotherapy-induced toxicity by irinotecan (CPT-11). Proc Natl Acad Sci U S A. 2013;110(47):19143\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"3755_CR10","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1177\/0091270006295060","volume":"47","author":"RP Ramchandani","year":"2007","unstructured":"Ramchandani RP, Wang Y, Booth BP, Ibrahim A, Johnson JR, Rahman A, et al. The role of SN-38 exposure, UGT1A1*28 polymorphism, and baseline bilirubin level in predicting severe irinotecan toxicity. J Clin Pharmacol. 2007;47(1):78\u201386.","journal-title":"J Clin Pharmacol"},{"issue":"7","key":"3755_CR11","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1200\/JCO.1996.14.7.2012","volume":"14","author":"R Mick","year":"1996","unstructured":"Mick R, Gupta E, Vokes EE, Ratain MJ. Limited-sampling models for irinotecan pharmacokinetics-pharmacodynamics: prediction of biliary index and intestinal toxicity. J Clin Oncol. 1996;14(7):2012\u20139.","journal-title":"J Clin Oncol"},{"key":"3755_CR12","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41522-017-0034-1","volume":"3","author":"L Guthrie","year":"2017","unstructured":"Guthrie L, Gupta S, Daily J, Kelly L. Human microbiome signatures of differential colorectal cancer drug metabolism. NPJ Biofilms Microbiomes. 2017;3:27.","journal-title":"NPJ Biofilms Microbiomes"},{"issue":"8","key":"3755_CR13","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1124\/dmd.121.000476","volume":"49","author":"MM Parvez","year":"2021","unstructured":"Parvez MM, Basit A, Jariwala PB, G\u00e1borik Z, Kis E, Heyward S, et al. Quantitative Investigation of Irinotecan Metabolism, Transport, and Gut Microbiome Activation. Drug Metab Dispos. 2021;49(8):683\u201393.","journal-title":"Drug Metab Dispos"},{"issue":"1\u20132","key":"3755_CR14","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/S0378-4347(97)00290-9","volume":"698","author":"P de Bruijn","year":"1997","unstructured":"de Bruijn P, Verweij J, Loos WJ, Nooter K, Stoter G, Sparreboom A. Determination of irinotecan (CPT-11) and its active metabolite SN-38 in human plasma by reversed-phase high-performance liquid chromatography with fluorescence detection. J Chromatogr B Biomed Sci Appl. 1997;698(1\u20132):277\u201385.","journal-title":"J Chromatogr B Biomed Sci Appl"},{"issue":"14","key":"3755_CR15","doi-asserted-by":"publisher","first-page":"3122","DOI":"10.1200\/JCO.2002.08.177","volume":"20","author":"DF Kehrer","year":"2002","unstructured":"Kehrer DF, Mathijssen RH, Verweij J, de Bruijn P, Sparreboom A. Modulation of irinotecan metabolism by ketoconazole. J Clin Oncol. 2002;20(14):3122\u20139.","journal-title":"J Clin Oncol"},{"key":"3755_CR16","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jchromb.2016.02.012","volume":"1015\u20131016","author":"S Basu","year":"2016","unstructured":"Basu S, Zeng M, Yin T, Gao S, Hu M. Development and validation of an UPLC-MS\/MS method for the quantification of irinotecan, SN-38 and SN-38 glucuronide in plasma, urine, feces, liver and kidney: Application to a pharmacokinetic study of irinotecan in rats. J Chromatogr B Analyt Technol Biomed Life Sci. 2016;1015\u20131016:34\u201341.","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"10","key":"3755_CR17","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1111\/bph.14987","volume":"177","author":"T Boeing","year":"2020","unstructured":"Boeing T, de Souza P, Speca S, Somensi LB, Mariano LNB, Cury BJ, et al. Luteolin prevents irinotecan-induced intestinal mucositis in mice through antioxidant and anti-inflammatory properties. Br J Pharmacol. 2020;177(10):2393\u2013408.","journal-title":"Br J Pharmacol"},{"issue":"5","key":"3755_CR18","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1080\/15376516.2024.2316003","volume":"34","author":"Z Zheng","year":"2024","unstructured":"Zheng Z, Du T, Gao S, Yin T, Li L, Zhu L, et al. Optimized rat models better mimic patients with irinotecan-induced severe diarrhea. Toxicol Mech Methods. 2024;34(5):572\u201383.","journal-title":"Toxicol Mech Methods"},{"issue":"1","key":"3755_CR19","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1258\/la.2011.011021","volume":"46","author":"E Gouma","year":"2012","unstructured":"Gouma E, Simos Y, Verginadis I, Lykoudis E, Evangelou A, Karkabounas S. A simple procedure for estimation of total body surface area and determination of a new value of Meeh\u2019s constant in rats. Lab Anim. 2012;46(1):40\u20135.","journal-title":"Lab Anim"},{"issue":"8","key":"3755_CR20","doi-asserted-by":"publisher","first-page":"3444","DOI":"10.1016\/j.apsb.2023.01.011","volume":"13","author":"S Song","year":"2023","unstructured":"Song S, Sun D, Wang H, Wang J, Yan H, Zhao X, et al. Full-profile pharmacokinetics, anticancer activity and toxicity of an extended release trivalent PEGylated irinotecan prodrug. Acta Pharmaceutica Sinica B. 2023;13(8):3444\u201353.","journal-title":"Acta Pharmaceutica Sinica B"},{"issue":"4","key":"3755_CR21","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s00280-007-0512-x","volume":"61","author":"M Onoue","year":"2008","unstructured":"Onoue M, Kurita A, Kado S, Matsumoto T, Kaneda N, Uchida K, et al. Involvement of UDP-glucuronosyltransferase activity in irinotecan-induced delayed-onset diarrhea in rats. Cancer Chemother Pharmacol. 2008;61(4):595\u2013605.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"12","key":"3755_CR22","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1039\/C7CC07668A","volume":"54","author":"LA Serrano","year":"2018","unstructured":"Serrano LA, Yang Y, Salvati E, Stellacci F, Krol S, Guldin S. pH-Mediated molecular differentiation for fluorimetric quantification of chemotherapeutic drugs in human plasma. Chem Commun (Camb). 2018;54(12):1485\u20138.","journal-title":"Chem Commun (Camb)"},{"issue":"12","key":"3755_CR23","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1002\/jsfa.6564","volume":"94","author":"VT \u0160aponjac","year":"2014","unstructured":"\u0160aponjac VT, Giron\u00e9s-Vilaplana A, Djilas S, Mena P, Cetkovi\u0107 G, Moreno DA, et al. Anthocyanin profiles and biological properties of caneberry (Rubus spp.) press residues. J Sci Food Agric. 2014;94(12):2393\u2013400.","journal-title":"J Sci Food Agric."},{"key":"3755_CR24","first-page":"987692","volume":"2013","author":"N Kannan","year":"2013","unstructured":"Kannan N, Sakthivel KM, Guruvayoorappan C. Protective Effect of Acacia nilotica (L.) against Acetaminophen-Induced Hepatocellular Damage in Wistar Rats. Adv Pharmacol Sci. 2013;2013:987692.","journal-title":"Adv Pharmacol Sci"},{"key":"3755_CR25","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jpba.2017.07.025","volume":"148","author":"C Yun","year":"2018","unstructured":"Yun C, Dashwood WM, Kwong LN, Gao S, Yin T, Ling Q, et al. Accurate quantification of PGE(2) in the polyposis in rat colon (Pirc) model by surrogate analyte-based UPLC-MS\/MS. J Pharm Biomed Anal. 2018;148:42\u201350.","journal-title":"J Pharm Biomed Anal"},{"issue":"6","key":"3755_CR26","first-page":"1721","volume":"50","author":"N Kaneda","year":"1990","unstructured":"Kaneda N, Yokokura T. Nonlinear pharmacokinetics of CPT-11 in rats. Cancer Res. 1990;50(6):1721\u20135.","journal-title":"Cancer Res"},{"issue":"4","key":"3755_CR27","first-page":"423","volume":"28","author":"JG Slatter","year":"2000","unstructured":"Slatter JG, Schaaf LJ, Sams JP, Feenstra KL, Johnson MG, Bombardt PA, et al. Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients. Drug Metab Dispos. 2000;28(4):423\u201333.","journal-title":"Drug Metab Dispos."},{"key":"3755_CR28","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1097\/00001813-200106000-00003","volume":"12","author":"W Yamamoto","year":"2001","unstructured":"Yamamoto W, Verweij J, Bruijn P, Jonge M, Takano H, Nishiyama M, et al. Active transepithelial transport of irinotecan (CPT-11) and its metabolites by human intestinal Caco-2 cells. Anticancer Drugs. 2001;12:419\u201332.","journal-title":"Anticancer Drugs"},{"issue":"4","key":"3755_CR29","first-page":"1376","volume":"54","author":"M Ouyang","year":"2019","unstructured":"Ouyang M, Luo Z, Zhang W, Zhu D, Lu Y, Wu J, et al. Protective effect of curcumin against irinotecan-induced intestinal mucosal injury via attenuation of NF-\u03baB activation, oxidative stress and endoplasmic reticulum stress. Int J Oncol. 2019;54(4):1376\u201386.","journal-title":"Int J Oncol"},{"key":"3755_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mam.2016.04.007","volume":"49","author":"KJ Davies","year":"2016","unstructured":"Davies KJ. Adaptive homeostasis. Mol Aspects Med. 2016;49:1\u20137.","journal-title":"Mol Aspects Med"},{"issue":"9","key":"3755_CR31","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/s41573-021-00233-1","volume":"20","author":"HJ Forman","year":"2021","unstructured":"Forman HJ, Zhang H. Targeting oxidative stress in disease: promise and limitations of antioxidant therapy. Nat Rev Drug Discov. 2021;20(9):689\u2013709.","journal-title":"Nat Rev Drug Discov"},{"key":"3755_CR32","doi-asserted-by":"publisher","first-page":"414","DOI":"10.3389\/fphar.2016.00414","volume":"7","author":"RM McQuade","year":"2016","unstructured":"McQuade RM, Stojanovska V, Abalo R, Bornstein JC, Nurgali K. Chemotherapy-induced constipation and diarrhea: pathophysiology, current and emerging treatments. Front Pharmacol. 2016;7:414.","journal-title":"Front Pharmacol."}],"updated-by":[{"DOI":"10.1007\/s11095-024-03774-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T00:00:00Z","timestamp":1727654400000}}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-024-03755-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11095-024-03755-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-024-03755-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T21:05:02Z","timestamp":1727730302000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11095-024-03755-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,13]]},"references-count":32,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["3755"],"URL":"https:\/\/doi.org\/10.1007\/s11095-024-03755-6","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s11095-024-03774-3","asserted-by":"object"}]},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,13]]},"assertion":[{"value":"29 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s11095-024-03774-3","URL":"https:\/\/doi.org\/10.1007\/s11095-024-03774-3","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Dr. Ming Hu and Dr. Rashim Singh are co-founders of Sanarentero LLC. Dr. Vesna Tumbas \u0160aponjac also has a financial interest in Sanarentero LLC. All other authors declare that they have no conflicting interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interests"}}]}}